ATE272623T1 - Inhibition von amyloid protein aggregation und bilderzeugung von amyloidniederschlägen mit isoindolderivate - Google Patents

Inhibition von amyloid protein aggregation und bilderzeugung von amyloidniederschlägen mit isoindolderivate

Info

Publication number
ATE272623T1
ATE272623T1 AT00938023T AT00938023T ATE272623T1 AT E272623 T1 ATE272623 T1 AT E272623T1 AT 00938023 T AT00938023 T AT 00938023T AT 00938023 T AT00938023 T AT 00938023T AT E272623 T1 ATE272623 T1 AT E272623T1
Authority
AT
Austria
Prior art keywords
amyloid
precipitations
inhibition
imaging
protein aggregation
Prior art date
Application number
AT00938023T
Other languages
English (en)
Inventor
Corinne Elizab Augelli-Szafran
Yingjie Lai
Annette Theresa Sakkab
Lary Craswell Walker
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of ATE272623T1 publication Critical patent/ATE272623T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Radiology & Medical Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT00938023T 1999-06-10 2000-05-31 Inhibition von amyloid protein aggregation und bilderzeugung von amyloidniederschlägen mit isoindolderivate ATE272623T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13854399P 1999-06-10 1999-06-10
PCT/US2000/015073 WO2000076969A1 (en) 1999-06-10 2000-05-31 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using isoindoline derivatives

Publications (1)

Publication Number Publication Date
ATE272623T1 true ATE272623T1 (de) 2004-08-15

Family

ID=22482508

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00938023T ATE272623T1 (de) 1999-06-10 2000-05-31 Inhibition von amyloid protein aggregation und bilderzeugung von amyloidniederschlägen mit isoindolderivate

Country Status (38)

Country Link
EP (1) EP1192131B1 (de)
JP (1) JP2003502313A (de)
KR (1) KR20020012266A (de)
CN (1) CN1156445C (de)
AP (1) AP1398A (de)
AT (1) ATE272623T1 (de)
AU (1) AU777747B2 (de)
BG (1) BG106291A (de)
BR (1) BR0011446A (de)
CA (1) CA2373394A1 (de)
CR (1) CR6530A (de)
CZ (1) CZ20014366A3 (de)
DE (1) DE60012742T2 (de)
DK (1) DK1192131T3 (de)
DZ (1) DZ3262A1 (de)
EA (1) EA004405B1 (de)
EE (1) EE200100666A (de)
ES (1) ES2223531T3 (de)
GE (1) GEP20043407B (de)
HK (1) HK1046283B (de)
HR (1) HRP20020027A2 (de)
HU (1) HUP0201586A2 (de)
IL (1) IL146455A0 (de)
IS (1) IS6162A (de)
MA (1) MA26807A1 (de)
MX (1) MXPA01011112A (de)
NO (1) NO20015992L (de)
NZ (1) NZ515619A (de)
OA (1) OA11958A (de)
PL (1) PL352294A1 (de)
PT (1) PT1192131E (de)
SI (1) SI1192131T1 (de)
SK (1) SK17622001A3 (de)
TR (1) TR200200257T2 (de)
UA (1) UA64842C2 (de)
WO (1) WO2000076969A1 (de)
YU (1) YU86801A (de)
ZA (1) ZA200109164B (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6972287B1 (en) 1999-06-10 2005-12-06 Pfizer Inc. Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
NZ515621A (en) * 1999-06-10 2004-05-28 Warner Lambert Co Medicaments for inhibiting amyloid protein aggregation and methods of imaging amyloid deposits
PE20020394A1 (es) 2000-08-18 2002-06-21 Agouron Pharma Compuestos de pirazol y composiciones farmaceuticas que los contienen, que modulan y/o inhiben la actividad de erab/hadh2
CA2357450A1 (en) * 2000-09-29 2002-03-29 Warner-Lambert Company Phenoxazine analogs useful as amyloid aggregation inhibitors and treatment of alzheimer's disease and disorders related to amyloidosis
GB0031302D0 (en) * 2000-12-21 2001-01-31 Glaxo Group Ltd Napthalene derivatives
AR042206A1 (es) * 2002-11-26 2005-06-15 Novartis Ag Acidos fenilaceticos y derivados
GB2404855A (en) * 2003-07-07 2005-02-16 Pantherix Ltd Arylcarboxylic acid derivatives and their therapeutic use
AR061623A1 (es) 2006-06-26 2008-09-10 Novartis Ag Derivados de acido fenilacetico
CA2670418A1 (en) * 2006-11-24 2008-05-29 Ac Immune Sa N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimers's
EP2121633A2 (de) 2007-02-12 2009-11-25 Merck & Co., Inc. Piperazinderivate zur behandlung von alzheimer-krankheit und verwandten leiden
KR101787112B1 (ko) * 2008-06-09 2017-11-15 루드비히-막시밀리안스-우니버지테트 뮌헨 신경변성 질환 및/또는 단백질 응집과 연관된 질환과 관련된 단백질의 응집을 억제하기 위한 신규 약물
EA019685B1 (ru) 2009-02-06 2014-05-30 Янссен Фармасьютикалз, Инк. Новые замещенные бициклические гетероциклические соединения в качестве модуляторов гамма-секретазы
TWI461425B (zh) 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
JP5559309B2 (ja) 2009-05-07 2014-07-23 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド γ分泌酵素調節物質としての新規置換インダゾールおよびアザインダゾール誘導体
KR20120050450A (ko) 2009-07-15 2012-05-18 얀센 파마슈티칼즈, 인코포레이티드 감마 세크레타제 조절제로서의 치환된 트리아졸 및 이미다졸 유도체
CA2784769A1 (en) 2010-01-15 2011-07-21 Janssen Pharmaceuticals, Inc. Novel substituted triazole derivatives as gamma secretase modulators
MX2013010970A (es) 2011-03-24 2013-10-17 Cellzome Ltd Novedosos derivados de triazolil piperazina y triazolil piperidina sustituidos como moduladores de gamma-secretasa.
ES2555167T3 (es) 2011-07-15 2015-12-29 Janssen Pharmaceuticals, Inc. Nuevos derivados de indol sustituidos como moduladores de gamma secretasa
JP6106745B2 (ja) 2012-05-16 2017-04-05 ヤンセン ファーマシューティカルズ，インコーポレーテッド （特に）アルツハイマー病の治療に有用な置換３，４−ジヒドロ−２Ｈ−ピリド［１，２−ａ］ピラジン−１，６−ジオン誘導体
AU2013366668B2 (en) 2012-12-20 2017-07-20 Janssen Pharmaceutica Nv Novel tricyclic 3,4-dihydro-2H-pyrido[1,2-alpha]pyrazine -1,6-dione derivatives as gamma secretase modulators
WO2014111457A1 (en) 2013-01-17 2014-07-24 Janssen Pharmaceutica Nv Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
MX368504B (es) * 2014-04-14 2019-10-04 Shanghai hengrui pharmaceutical co ltd Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos.
CA2959531C (en) * 2014-08-29 2023-01-10 Chdi Foundation, Inc. Probes for imaging huntingtin protein
NZ768373A (en) 2014-10-06 2024-03-22 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
WO2017173274A1 (en) 2016-03-31 2017-10-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US10570115B2 (en) 2016-09-30 2020-02-25 Vertex Pharmaceuticals Incorporated Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
AU2017371200B2 (en) 2016-12-09 2021-05-06 Vertex Pharmaceuticals Incorporated Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
WO2018140186A1 (en) * 2017-01-28 2018-08-02 Kingchem Life Science Llc A process for preparing 5-phenoxy-1(3h)isobenzofuranone
AU2018279646B2 (en) 2017-06-08 2023-04-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
BR112020000941A2 (pt) 2017-07-17 2020-07-21 Vertex Pharmaceuticals Incorporated métodos de tratamento para fibrose cística
ES2912657T3 (es) 2017-08-02 2022-05-26 Vertex Pharma Procesos para preparar compuestos de pirrolidina
CN109232533A (zh) * 2017-09-28 2019-01-18 北京越之康泰生物医药科技有限公司 氮杂环类衍生物、其制备方法及其医药用途
US10654829B2 (en) 2017-10-19 2020-05-19 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
KR20200097293A (ko) 2017-12-08 2020-08-18 버텍스 파마슈티칼스 인코포레이티드 낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
EP3774825A1 (de) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulatoren des transmembranleitfähigkeitsreglers von zystischer fibrose, pharmazeutische zusammensetzungen, behandlungsverfahren und verfahren zur herstellung des modulators
KR20240035820A (ko) 2021-07-09 2024-03-18 플렉시움 인코포레이티드 Ikzf2를 조절하는 아릴 화합물 및 약학 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552426A (en) * 1994-04-29 1996-09-03 Eli Lilly And Company Methods for treating a physiological disorder associated with β-amyloid peptide

Also Published As

Publication number Publication date
JP2003502313A (ja) 2003-01-21
TR200200257T2 (tr) 2002-06-21
KR20020012266A (ko) 2002-02-15
UA64842C2 (uk) 2004-03-15
SI1192131T1 (en) 2004-12-31
CZ20014366A3 (cs) 2002-11-13
NO20015992L (no) 2002-02-06
CN1355790A (zh) 2002-06-26
EA004405B1 (ru) 2004-04-29
EE200100666A (et) 2003-02-17
BR0011446A (pt) 2002-03-19
IL146455A0 (en) 2002-07-25
HK1046283B (zh) 2005-01-07
AU5312000A (en) 2001-01-02
CR6530A (es) 2004-03-24
MA26807A1 (fr) 2004-12-20
EA200101133A1 (ru) 2002-06-27
SK17622001A3 (sk) 2003-06-03
OA11958A (en) 2006-04-13
CN1156445C (zh) 2004-07-07
IS6162A (is) 2001-11-15
DE60012742T2 (de) 2005-01-13
AP2002002389A0 (en) 2002-03-31
NZ515619A (en) 2003-05-30
AU777747B2 (en) 2004-10-28
HK1046283A1 (en) 2003-01-03
ES2223531T3 (es) 2005-03-01
HUP0201586A2 (en) 2002-08-28
DZ3262A1 (fr) 2000-12-12
GEP20043407B (en) 2004-05-10
DK1192131T3 (da) 2004-12-13
NO20015992D0 (no) 2001-12-07
YU86801A (sh) 2004-07-15
AP1398A (en) 2005-04-21
WO2000076969A1 (en) 2000-12-21
PT1192131E (pt) 2004-11-30
ZA200109164B (en) 2003-02-06
PL352294A1 (en) 2003-08-11
MXPA01011112A (es) 2002-06-04
BG106291A (bg) 2002-05-31
DE60012742D1 (de) 2004-09-09
CA2373394A1 (en) 2000-12-21
HRP20020027A2 (en) 2005-02-28
EP1192131B1 (de) 2004-08-04
EP1192131A1 (de) 2002-04-03

Similar Documents

Publication Publication Date Title
ATE272623T1 (de) Inhibition von amyloid protein aggregation und bilderzeugung von amyloidniederschlägen mit isoindolderivate
DE69900746T2 (de) Gesteuerte verabreichung von peptiden oder proteinen
EE200100659A (et) Diaminotiasoolid ja nende kasutamine proteiinikinaaside pärssimiseks
CY2008019I2 (el) Υποκατεστημενες οξαζολιδινονες και η χρηση των στο πεδιο της πηξης αιματος
NO20021333D0 (no) Sammensetning som innbefatter kasein- og myseprotein
NO20004098D0 (no) FremgangsmÕter og preparater for behandling av makrofag- formidlede lidelser
NO20001242L (no) April - et nytt protein med veksteffekter
DE60034476D1 (de) Topische nasenbehandlung mit desloratadin und mometason furoat
DE50107978D1 (de) Salze von L-Aminosäuren mit verbessertem Geschmack und ihre Herstellung
DE60021485D1 (de) Filteranordnung mit Umlaufventil und Anzeigemittel
IS6181A (is) Ein- og tvíataðgengnar 3-própýl-gamma-amínósmjörsýrur
PT1143997E (pt) Antagonistas de factor de necrose tumoral e o seu uso no tratamento da endometriose
EE200100673A (et) Meetod amüloidvalgu agregatsiooni inhibeerimiseksja amüloiddeposiitide piltdiagnostika läbiviimiseks
DE69813602T2 (de) Venlafaxinhaltiges arzneimittel mit verlängerter wirkstoffabgabe
DE60009738D1 (de) Verbesserter ausguss und kapsel mit inkorporiertem ausguss
DE69940938D1 (de) Ausgabegerät von Aufzeichnungsträgern und Bilderzeugungsgerät ausgestattet mit diesem
DK0984788T3 (da) Farmaceutiske præparater af peptider med lav opløselighed i fysiologiske medier
DE69637780D1 (de) Nachweis von mutationen mittels in vitro synthetisierten proteinen mit peptid-markierung
DE60020939D1 (de) Salze von pharmakologisch aktiven peptiden mit verzögerter wirkstofffreigabe und deren herstellung
DE69722038D1 (de) Radiopharmazeutische mittel zur bildgebung von infektionen und entzündungen
ATE346840T1 (de) Aminoalkylphenol-derivate zur behandlung von depression und gedächtnis-funktionsstörung
DE69821227D1 (de) Verwendung von papovavirus kapsid-proteinen zur verabreichung therapeutischen agentien in nervzellen
NO20012606D0 (no) Forbindelse med inhibitorisk virkning på kolesteryloverförende protein samt fremstilling derav
NO20015115D0 (no) Adipocyttkomplementbeslektet proteinhomolog zacrp3
DE29802874U1 (de) Mehrteilige Pfeffer-Salz-Streuvorrichtung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1192131

Country of ref document: EP

REN Ceased due to non-payment of the annual fee